FDA approves two hepatitis C drugs for pediatric patients - FDA Press Releases

The U.S. Food and Drug Administration today approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Harvoni and Sovaldi were previously approved to treat HCV in adults.

from Food and Drug Administration--Press Releases http://ift.tt/2o5yDGq
via IFTTT